Genetic mutations have a strong association with the response to antiplatelet therapy. FDA has now approved genetic testing for clopidogrel response, before starting a patient electively on clopidogrel.
If you plan to start your patient on antiplatelets, you can now use GenePower Clopidogrel to know the response and treat accordingly. We ensure to generate non ambiguous, transparent reports, which the physician can easily incorporate into treatment plan.
We developed protocol to test not only metabolism but absorption as well. This test is ideal in pre procedure screening for elective heart catheterization or in patients already taking clopidogrel.